Navigation Links
Discovery of mechanism in brain cell injury in Huntington's offers new treatment approaches
Date:1/27/2010

Scientists at the Brain Research Centre and Centre for Molecular Medicine and Therapeutics have uncovered a key cellular mechanism that alters brain cell function in Huntington's disease, and identified a possible treatment for the disease.

The results of the study were published online today and will appear in the January 28 edition of the journal Neuron.

Huntington's disease is an inherited degenerative brain disease that causes cognitive and motor impairment, and eventually death. One in 10,000 Canadians suffers from Huntington's disease.

The researchers found that, in mouse models, the genetic mutation that causes Huntington's disease results in an excessive number of NMDA receptorsspecial receptors found at the surface of brain cellsto accumulate and be active outside synapses, which are the connections between brain cells. In healthy conditions, there should be few NMDA receptors outside the synapse.

The researchers also found that the over-activation of the NMDA receptors outside the synapse leads to a reduction in brain cell survival signals and disruption in brain function.

"Previous work in cell cultures showed that NMDA receptors located within the synapse can have beneficial effects on brain cells, whereas NMDA receptors outside the synapse, called 'extra-synaptic NMDA receptors,' have a detrimental effect," says Dr. Lynn Raymond, a professor in the UBC Department of Psychiatry, a member of the Brain Research Centre at UBC Hospital, and co-director of the Huntington's Disease Medical Clinic.

"Our study shows an increase in the number of extrasynaptic NMDA receptors, shifting the balance between these opposing cellular mechanisms in animal models of early stages of Huntington's disease," Raymond says.

While further work still needs to be done to determine how the genetic mutation causes the excessive number and activity of NMDA receptors to localize outside the synapses, the researchers did find a way to mitigate damage and slow disease progression at early stages of the diseaseusing Memantine, a drug currently used to treat Alzheimer's disease.

"Memantine in low dose works by preferentially blocking the activity of NMDA receptors outside the synapse," says Dr. Michael Hayden, director of the Centre for Molecular Medicine and Therapeutics, professor in the UBC Department of Medical Genetics, and co-author on the study.

"It was previously shown to reverse deficits and damage in late stages of animal models of Huntington's disease, but we found it could improve learning and cell survival signaling even at early stages of the disease," says Hayden. "A small human clinical trial of Memantine for Huntington's disease has also recently shown positive effects. Larger, international clinical trials are now being planned."

"Memantine's beneficial effects appear to be dose-specific," Raymond adds. "Before it can be prescribed to treat Huntington's disease, we need to know how to determine appropriate dosing and whether it interferes with other essential cellular and brain functions."


'/>"/>

Contact: Melissa Ashman
mashman@brain.ubc.ca
604-827-3396
University of British Columbia
Source:Eurekalert

Related medicine news :

1. Discovery of sugar sensor in intestine could benefit diabetes
2. Discovery suggests location of genes for breast density, a strong risk factor for breast cancer
3. Stem cell research produces a key discovery for Fragile X Syndrome
4. Welch Foundation gives $1.6 million for drug discovery research
5. New discovery leaves blood-doping athletes scratching their heads
6. Chemical Diversity Initiates International Prostrate Cancer Discovery Partnership
7. New discovery leaves blood-doping athletes scratching their heads
8. Discovery of widespread tumor growth gene holds promise for effective anti-cancer treatment
9. Discovery supports theory of Alzheimers disease as form of diabetes
10. Discovery Health CME Explores the Benefits and Risks of Aspirin in Aspirin Therapy: Maximizing the Benefits
11. New discovery may improve treatment of one of the worlds leading causes of blindness
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/24/2017)... KS (PRWEB) , ... January 24, 2017 , ... ... Premensa, a leading natural supplement for relieving premenstrual syndrome, or PMS . ... at some point. These symptoms can include cramps, constipation, irritability, headaches, fatigue, and ...
(Date:1/24/2017)... ... ... Novel of Miracles”: a beautiful and poignant glimpse into the unexpected consequences of a ... Would Have Dreamed: A Novel of Miracles” is the creation of published author, Sharon Lee ... shares that she started her spiritual journey later in life, but mentions, “I have had ...
(Date:1/24/2017)... ... 2017 , ... “The Octagon of Spiritual Balances”: a guide for the ... creation of published author, Pastor Bernard J. Weathers, pastor of Word of Faith Ministries, ... religious education and a master degree in theology. , ““The Octagon of Spiritual Balances” ...
(Date:1/24/2017)... Raton, FL (PRWEB) , ... January 23, 2017 ... ... unique, highly refined coffee house-caliber protein and espresso drink, announced its CLICK® Coffee ... nutritional products. , CLICK® Coffee Protein Drink Mix has become popular among health-conscious ...
(Date:1/24/2017)... ... January 23, 2017 , ... United Nations Foundation ... of the Mexico City Policy, also known as the Global Gag Rule, last ... action, prohibits foreign non-governmental organizations from receiving any U.S. foreign assistance for family ...
Breaking Medicine News(10 mins):
(Date:1/24/2017)... FRANCISCO , January 24, 2017 ... a value of USD 3.8 billion by 2025, according ... The market growth can be attributed to the rising ... about early diagnosis of micro calcifications in breast tissue. ... Foundation, CDC, and Breast Cancer Organization are promoting the ...
(Date:1/24/2017)... Stock-Callers.com today has issued research reports on four ... Mallinckrodt PLC (NYSE: MNK ), Akorn Inc. (NASDAQ: ... DPLO ). According to pharmaceutical manufacturer PCI Synthesis, there ... Generic Drugs industry, including a possible reduction in FDA red ... a speedier FDA approval process that could reduce its backlog ...
(Date:1/24/2017)... 2017 Optoelectronic components have the capability ... interaction of these components with light makes them ... of applications. These components are primarily used in ... healthcare among others. Growing application across ... power consumption, reliability, scalability, and performance is fueling ...
Breaking Medicine Technology: